| Dr Gregory J Yanish, MD | |
|
12499 University Ave, Ste. 210, Clive, IA 50325-8288 | |
| (515) 440-2676 | |
| (515) 440-2677 |
| Full Name | Dr Gregory J Yanish |
|---|---|
| Gender | Male |
| Speciality | Hand Surgery |
| Experience | 23 Years |
| Location | 12499 University Ave, Clive, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497809859 | NPI | - | NPPES |
| 4982685 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 5315021056 (Michigan) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Capital Orthopaedics And Sports Medicine Pc | 3476691551 | 19 |
News Archive
The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer leading the UK-Rapid Test Consortium, has received its CE mark. This means it is approved for professional use in the UK and EU.
A subtle change to hospital data collection policies could make a big difference in preventing occupational health and safety hazards, according to workplace safety researchers at the Drexel University School of Public Health.
How much is it worth to you and your family to have a health insurance plan that covers the latest innovations in adult and childhood vaccines for certain types of cancer or even influenza and pneumonia?
Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.
Improved risk classification for patients with acute lymphoblastic leukemia (ALL), coupled with more intensive intrathecal chemotherapy for high risk patients and the use of a drug called dexamethasone, could one day permit physicians to omit irradiation as a part of routine treatment.
› Verified 5 days ago
| Entity Name | Dallas County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861416307 PECOS PAC ID: 9931094257 Enrollment ID: O20040217000157 |
News Archive
The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer leading the UK-Rapid Test Consortium, has received its CE mark. This means it is approved for professional use in the UK and EU.
A subtle change to hospital data collection policies could make a big difference in preventing occupational health and safety hazards, according to workplace safety researchers at the Drexel University School of Public Health.
How much is it worth to you and your family to have a health insurance plan that covers the latest innovations in adult and childhood vaccines for certain types of cancer or even influenza and pneumonia?
Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.
Improved risk classification for patients with acute lymphoblastic leukemia (ALL), coupled with more intensive intrathecal chemotherapy for high risk patients and the use of a drug called dexamethasone, could one day permit physicians to omit irradiation as a part of routine treatment.
› Verified 5 days ago
| Entity Name | Capital Orthopaedics And Sports Medicine Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932432457 PECOS PAC ID: 3476691551 Enrollment ID: O20091110000451 |
News Archive
The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer leading the UK-Rapid Test Consortium, has received its CE mark. This means it is approved for professional use in the UK and EU.
A subtle change to hospital data collection policies could make a big difference in preventing occupational health and safety hazards, according to workplace safety researchers at the Drexel University School of Public Health.
How much is it worth to you and your family to have a health insurance plan that covers the latest innovations in adult and childhood vaccines for certain types of cancer or even influenza and pneumonia?
Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.
Improved risk classification for patients with acute lymphoblastic leukemia (ALL), coupled with more intensive intrathecal chemotherapy for high risk patients and the use of a drug called dexamethasone, could one day permit physicians to omit irradiation as a part of routine treatment.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gregory J Yanish, MD 12499 University Ave, Ste. 210, Clive, IA 50325-8288 Ph: (515) 440-2676 | Dr Gregory J Yanish, MD 12499 University Ave, Ste. 210, Clive, IA 50325-8288 Ph: (515) 440-2676 |
News Archive
The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer leading the UK-Rapid Test Consortium, has received its CE mark. This means it is approved for professional use in the UK and EU.
A subtle change to hospital data collection policies could make a big difference in preventing occupational health and safety hazards, according to workplace safety researchers at the Drexel University School of Public Health.
How much is it worth to you and your family to have a health insurance plan that covers the latest innovations in adult and childhood vaccines for certain types of cancer or even influenza and pneumonia?
Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.
Improved risk classification for patients with acute lymphoblastic leukemia (ALL), coupled with more intensive intrathecal chemotherapy for high risk patients and the use of a drug called dexamethasone, could one day permit physicians to omit irradiation as a part of routine treatment.
› Verified 5 days ago
Samuel M Maurice, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1601 Nw 114th St Ste 151, Clive, IA 50325 Phone: 515-643-5455 Fax: 515-643-6459 | |
Devon L Foster, DO Surgery Medicare: Medicare Enrolled Practice Location: 1601 Nw 114th St Ste 151, Clive, IA 50325 Phone: 515-222-7474 Fax: 515-222-7491 | |
Ryan Dornbier, Surgery Medicare: Accepting Medicare Assignments Practice Location: 12129 University Ave Ste 100, Clive, IA 50325 Phone: 515-400-3550 Fax: 515-400-3551 | |
Susan L Beck, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 1601 Nw 114th St Ste 151, Clive, IA 50325 Phone: 515-222-7474 Fax: 515-222-7491 | |
Tiffany A Torstenson, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1601 Nw 114th St Ste 151, Clive, IA 50325 Phone: 515-222-7474 Fax: 515-222-7491 | |
Kathryn Elizabeth Hallberg Skibba, MD Surgery Medicare: Medicare Enrolled Practice Location: 1601 Nw 114th St Ste 151, Clive, IA 50325 Phone: 515-643-5455 Fax: 515-643-6459 |